H.C. Wainwright lowered the firm’s price target on Spero Therapeutics (SPRO) to $5 from $7 and keeps a Buy rating on the shares. The company’s SPR720 Phase 2a data disappointed, the analyst tells investors in a research note. The firm completely remoted the candidate from its valuation assessment.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter